Shuxia Wang1, Bo Yuan2, Yun Wang1, Mingyang Li1, Xibo Liu1, Jing Cao1, Changtian Li2, Jihong Hu3. 1. Public Health School, Gansu University of Chinese Medicine, Lanzhou, 730000, China. 2. Basic Medical School, Gansu University of Chinese Medicine, Lanzhou, 730000, China. 3. Center of Research and Experiment, Gansu University of Chinese Medicine, Lanzhou, 730000, China. hujihonghappy@163.com.
Abstract
PURPOSE: To systematically evaluate the correlation between PD-L1 expression and clinicopathological features and prognosis of colorectal cancer (CRC). METHODS: Seven databases (PubMed, Cochrane Library, EMBASE, Web of Science, CBM, Wanfang, and CNKI) were searched through May 2020. Risk of bias and quality of evidence were assessed by using the Newcastle-Ottawa scale (NOS), and meta-analysis was carried out by using the Review Manager 5.3 software on the studies with the quality evaluation scores ≥ 6. Meta-regression analysis was used to determine the independent role of PD-L1 expression on CRC prognosis after adjusting clinicopathological features and treatment methods. RESULTS: A total of 8823 CRC patients in 32 eligible studies. PD-L1 expression was correlated with lymphatic metastasis (yes/no; OR = 1.24, 95% CI (1.11, 1.38)), diameter of tumor (≥ 5 cm/< 5 cm; OR = 1.34, 95% CI (1.06, 1.70)), differentiation (high-middle/low; OR = 0.68, 95% CI (0.53, 0.87)), and vascular invasion (yes/no; OR = 0.80, 95% CI (0.69, 0.92)). PD-L1 expression shortened the overall survival (hazard ratio (HR) = 1.93, 95% CI (1.66, 2.25)), disease-free survival (HR = 1.76, 95% CI (1.50, 2.07)), and progression-free survival (HR = 1.93, 95% CI (1.55, 2.41)). Meta-regression showed that PD-L1 expression played a significant role on poor CRC OS (HR = 1.95, 95% CI (1.92, 3.98)) and disease-free survival (HR = 2.14, 95% CI (0.73, 4.52)). CONCLUSION: PD-L1 expression independently predicted a poor prognosis of CRC.
PURPOSE: To systematically evaluate the correlation between PD-L1 expression and clinicopathological features and prognosis of colorectal cancer (CRC). METHODS: Seven databases (PubMed, Cochrane Library, EMBASE, Web of Science, CBM, Wanfang, and CNKI) were searched through May 2020. Risk of bias and quality of evidence were assessed by using the Newcastle-Ottawa scale (NOS), and meta-analysis was carried out by using the Review Manager 5.3 software on the studies with the quality evaluation scores ≥ 6. Meta-regression analysis was used to determine the independent role of PD-L1 expression on CRC prognosis after adjusting clinicopathological features and treatment methods. RESULTS: A total of 8823 CRC patients in 32 eligible studies. PD-L1 expression was correlated with lymphatic metastasis (yes/no; OR = 1.24, 95% CI (1.11, 1.38)), diameter of tumor (≥ 5 cm/< 5 cm; OR = 1.34, 95% CI (1.06, 1.70)), differentiation (high-middle/low; OR = 0.68, 95% CI (0.53, 0.87)), and vascular invasion (yes/no; OR = 0.80, 95% CI (0.69, 0.92)). PD-L1 expression shortened the overall survival (hazard ratio (HR) = 1.93, 95% CI (1.66, 2.25)), disease-free survival (HR = 1.76, 95% CI (1.50, 2.07)), and progression-free survival (HR = 1.93, 95% CI (1.55, 2.41)). Meta-regression showed that PD-L1 expression played a significant role on poor CRC OS (HR = 1.95, 95% CI (1.92, 3.98)) and disease-free survival (HR = 2.14, 95% CI (0.73, 4.52)). CONCLUSION:PD-L1 expression independently predicted a poor prognosis of CRC.
Entities:
Keywords:
Clinicopathological features; Colorectal cancer (CRC); Meta-analysis; Prognosis; Programmed death ligand-1 (PD-L1)
Authors: K Abiko; N Matsumura; J Hamanishi; N Horikawa; R Murakami; K Yamaguchi; Y Yoshioka; T Baba; I Konishi; M Mandai Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Zhaoying Wu; Lin Yang; Linsen Shi; Hu Song; Peicong Shi; Ting Yang; Ruizhi Fan; Tao Jiang; Jun Song Journal: Biomed Res Int Date: 2019-06-03 Impact factor: 3.411
Authors: Bella Steiner; Leah M Ferrucci; Lisa Mirabello; Qing Lan; Wei Hu; Linda M Liao; Sharon A Savage; Immaculata De Vivo; Richard B Hayes; Preetha Rajaraman; Wen-Yi Huang; Neal D Freedman; Erikka Loftfield Journal: PLoS One Date: 2020-01-08 Impact factor: 3.240